New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For RAD;VVUS;NYX;FOLD;CAG;ORCL;MDRX;DFS;JBL;ELOQ;ICE;BBBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
September 18, 2014
14:54 EDTORCLOracle technical comments ahead of results
In the past three months the stock has underperformed, falling by over 3%. The trading in shares has been relatively volatile, but within a narrow range largely contained by $40 at the low and $42 at the high. If the news is stronger than expected, particularly where outlook is concerned, there could be a run to the 52-week high at $43.19. That high is very close to the life highs for the shares at $46.18. We could see a range open up between the 52-week high and the life high if news exceeds expectations. If the news fails to meet investor expectations, a test down to the $40 area would appear very likely. A break below $40 would see next support at $38.34 and then at $37.08. The stock can be volatile around earnings, but gaps tend to be relatively small unless estimates are broken in extreme fashion, in either direction.
14:09 EDTVVUSVIVUS rallies, mean-reverting to intraday trend line
The shares have traded in an extremely wide range today on nearly 20 times daily average volume. An intraday trend line appears currently to be broken. That line is at $4.60 now, and projecting forward would be at the $4.80 area by the close. At the current price of $4.50, support is at $4.41 and then at $4.32.
13:00 EDTJBLJabil Circuits October volatility increases into Q4
Jabil Circuits October call option implied volatility is at 34, December is at 29, January is at 28, compared to its 26-week average of 28 according to Track Data, suggesting slightly larger near term price movement into the expected release of Q4 results after the market close on September 24.
12:58 EDTORCLEarnings Preview: Morgan Stanley views Oracle's Q1, Q2 estimates as 'achievable'
Subscribe for More Information
12:45 EDTCAG, RAD, VVUSOn The Fly: Midday Wrap
Subscribe for More Information
11:55 EDTRADRite Aid falls as drugstore chain trims FY15 view
Subscribe for More Information
10:40 EDTBBBYPier 1 Imports falls to 12-month low after weak Q2, lowered outlook
Shares of home furnishings retailer Pier 1 Imports (PIR) hit a 12-month low after the company's second quarter results fell below analysts' consensus estimates and it reduced its fiscal 2015 earnings per share outlook. WHAT'S NEW: Pier 1 Imports reported Q2 EPS of 10c on revenue of $418.6M, missing analysts' consensus estimates of 14c and $426.02M, respectively. Same-store-sales for the quarter were up 4.5%. The retailer lowered its FY15 EPS outlook to 95c-$1.05 from $1.14-$1.22. Analysts' consensus estimates for FY15 EPS prior to the earnings report was $1.13. The company sees FY15 SSS in the mid-to-high single digits and gross profit, as a percentage of sales, are expected to be 40.5%-41.5%. Pier 1 Imports CEO Alex Smith said that he foresees online sales to surpass $400M in 2016. WHAT'S NOTABLE: During the company's conference call, Pier 1 Imports said that it expects to see improving merchandise margins in coming quarters with fewer coupons. The company noted plans to continue returning cash to shareholders in the form of dividends and share buybacks. ANALYST REACTION: This morning, Wells Fargo analyst Matt Neemer downgraded Pier 1 Imports to Market Perform from Outperform. He feels that the stock will be a difficult one to own in the medium term as the retailer moves towards a multi-channel approach. Neemer believes that the company has a difficult journey ahead as it cuts broad-based discounters, and he feels that consumers will take time to get accustomed to the new messaging. He cut his price target range to $15-$16 from $19-$20 for the company. Barclays analyst Alan Rifkin downgraded Pier 1 Imports to Equal Weight from Overweight due to slow revenue growth and heightened promotions. He feels that that the "soft" revenues could continue. He believes that the company's elongated online profitability pipeline and increased promotions are certain to be a burden on the business in ways that the company had not initially thought. Rifkin said that growing the top line will be even harder in the absence of promotions. He reduced his price target for shares to $14 from $18. Argus analyst Christopher Graja downgraded Pier 1 Imports to Hold from Buy due to the company's lower than anticipated Q2 earnings. He feels that in terms of the home furnishings market, companies such as Williams-Sonoma (WSM), Home Depot (HD) and Lowe's (LOW) are more "resilient" for shareholders. Pier 1 Imports was also downgraded to Hold from Buy at BB&T. PRICE ACTION: In morning trading, Pier 1 Imports fell $2.63, or 16.99%, to $12.90. Including today's pull back, the stock is down approximately 45.2% over the past 12 months. OTHERS TO WATCH: Other companies in the home furnishings space include Restoration Hardware (RH), and Bed Bath & Beyond (BBBY).
10:27 EDTCAG, RADOptions with decreasing implied volatility
Subscribe for More Information
10:03 EDTCAGConAgra says to limit share repurchases as company delevers
Subscribe for More Information
09:36 EDTVVUS, RADActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL YHOO TWTR VVUS RAD PWE WFM TSLA PIR SHLD
09:15 EDTRADRite Aid remains 'optimistic' about FY16
Subscribe for More Information
09:02 EDTRADRite Aid sees current competitive enviornment to remain promotional in FY15
Subscribe for More Information
08:59 EDTVVUS, RAD, CAGOn The Fly: Pre-market Movers
Subscribe for More Information
07:37 EDTCAGConAgra sees Q2 comparable EPS in line with 2Q14
Comparable EPS for the 2Q15 is expected to be in line with year-ago amounts given the strong comparable EPS performance in 2Q14. Q2 EPS consensus 61c.
07:34 EDTCAGConAgra backs FY15 EPS view of mid-single digit rate growth vs. FY14
Subscribe for More Information
07:33 EDTCAGConAgra reaffirms commitment to maintaining strong dividend
Subscribe for More Information
07:32 EDTCAGConAgra reports Q1 adjusted EPS 39c, consensus 35c
Reports Q1 revenue $3.7B, consensus $3.73B. Gary Rodkin, ConAgra Foods’ CEO, said, “We are pleased with the good start to fiscal 2015, which demonstrates improving fundamentals and better execution. Volume for Consumer Foods is recovering, Lamb Weston’s foodservice channel sales are robust, and cost savings programs across the company are coming in as planned. We remain confident that fiscal 2015 will be a year of stabilization and recovery, and I look forward to updating you on our progress throughout the fiscal year.”
07:04 EDTRADRite Aid cuts FY15 EPS view to 22c-33c, consensus 34c
Based upon current estimates for reimbursement rates and anticipated lower profitability from new generics and generic drugs that recently lost exclusivity, the company is expecting decreases in pharmacy margin in the second half of Fiscal 2015 as compared to its prior estimates and therefore is lowering its guidance for Adjusted EBITDA, net income and net income per diluted share. Previous EPS view was 30c-40c. Cuts FY15 high end of revenue view to $26B-$26.3B from $26B-$26.5B, consensus $26.29B. Now sees FY SSS up 3%-4% over FY14. Sees FY CapEx $525M. Sees adjusted EBITDA $1.2B-$1.275B.
07:02 EDTRADRite Aid reports Q2 EPS 13c, consensus 6c
Subscribe for More Information
06:05 EDTVVUSVIVUS, Auxilium announce FDA approval of STENDRA sNDA
VIVUS (VVUS) and Auxilium Pharmaceuticals (AUXL) announced that the FDA has approved a supplemental new drug application, or sNDA, for STENDRA. STENDRA is now the only FDA-approved erectile dysfunction, or ED, medication indicated to be taken as early as approximately 15 minutes before sexual activity. STENDRA is a prescription medication in a class of drugs known as phosphodiesterase type 5, or PDE5, inhibitors approved for the treatment of ED in men 18 years or older. STENDRA is available in multiple dosage strengths and may be taken with or without food and moderate alcohol consumption. In clinical studies, when compared to placebo, STENDRA helped more men achieve an erection in as early as approximately 15 minutes that lasted long enough to successfully complete sexual intercourse.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use